Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + bendamustine + cytarabine in relapsed or refractory diffuse large B-cell lymphoma (Phase II)
2015-005837-37Phase 2Terminated
- Sponsor
- CHU Caen Normandie
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, bendamustine and cytarabine in diffuse large B-cell lymphoma (DLBCL), sponsored by CHU Caen Normandie. Primary endpoint: Overall response rate (ORR). Started Apr 2016; status: terminated.
02
Drugs
rituximabbendamustinecytarabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2015-005837-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005837-37.